Gilead Sciences Shares Rally 1.00% Amid 162nd-Ranked 570M Volume Drop as FDA Hurdles Loom

On September 26, 2025, Gilead Sciences (GILD) closed with a 1.00% gain, despite a 39.15% decline in daily trading volume to $570 million, ranking it 162nd in market activity. The biopharmaceutical giant's shares showed resilience amid mixed sector performance, with analysts noting limited catalysts in the near-term pipeline as a potential factor in the volume contraction.

Recent regulatory developments surrounding the company's antiviral therapies sparked muted investor interest. A pending FDA advisory panel meeting on November 3rd regarding expanded labeling for a key hepatitis C treatment remains the primary event risk. Short-term options positioning has remained neutral, with open interest concentrated in at-the-money strike prices ahead of the anticipated regulatory decision.

Technical indicators suggest the stock is consolidating within a $138-$142 range, with the 200-day moving average acting as a critical support level. The 52-week range of $128.34 to $149.71 provides a reference for potential breakout scenarios. Market participants are closely monitoring the company's Q3 earnings report scheduled for October 10th, which could provide directional clarity following the recent volume contraction.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in moderate performance. The annualized return was 5.3%, with a total profit of $1,647.6 over the past year. However, the strategy had some drawdowns, with the largest loss occurring on October 26, 2024, when a -4.2% drop led to a temporary loss of $532.4. Overall, the strategy provided steady returns but came with volatility and risk.